Indications for Prognostic Gene Expression Profiling in Early Breast Cancer

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

(2014) Torsten Nielsen et al.   BMC CANCER

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

(2014) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

(2014) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

(2013) M. Gnant et al.   ANNALS OF ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

(2013) P Dubsky et al.   BRITISH JOURNAL OF CANCER

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

(2013) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

(2013) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

(2013) Dennis C Sgroi et al.   LANCET ONCOLOGY

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients

(2012) F. Bertucci et al.   ANNALS OF ONCOLOGY

A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

(2012) S. K. Chia et al.   CLINICAL CANCER RESEARCH

Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!

(2012) Daniel F. Hayes   JOURNAL OF CLINICAL ONCOLOGY

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections

(2012) Berit Maria Müller et al.   JOURNAL OF CLINICAL PATHOLOGY

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay

(2012) Carsten Denkert et al.   VIRCHOWS ARCHIV

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

(2011) P-L Jerevall et al.   BRITISH JOURNAL OF CANCER

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

(2011) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial

(2011) John M.S. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

(2010) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

(2009) Steven M Teutsch et al.   GENETICS IN MEDICINE

Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer

(2009) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

Epidemiology of Locally Advanced Breast Cancer

(2009) Lisa A. Newman   SEMINARS IN RADIATION ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design

(2008) Margaret S. Pepe et al.   JNCI-Journal of the National Cancer Institute